How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Buy
53
PBE Quote, Financials, Valuation and Earnings
Last price:
$67.47
Seasonality move
:
1.72%
Day range:
$67.18 - $67.59
52-week range:
$59.32 - $72.84
Dividend yield:
0.05%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.7K
Avg. volume:
6.8K
1-year change:
2.71%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
$67.46 | -- | -- | -- | $0.01 | 0.05% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$24.49 | -- | -- | -- | $0.24 | 0.98% | -- |
|
BBH
VanEck Biotech ETF
|
$158.96 | -- | -- | -- | $1.25 | 0.79% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$83.00 | -- | -- | -- | $0.22 | 0.97% | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
$40.89 | -- | -- | -- | $0.03 | 0.06% | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$43.41 | -- | -- | -- | $0.15 | 1.56% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.301 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.890 | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | 1.127 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | 0.832 | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | 1.936 | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 1.021 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Invesco Biotechnology & Genome ETF vs. Competitors
-
Which has Higher Returns PBE or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About PBE or BBC?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is PBE or BBC More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.819, which suggesting that the stock is 18.07% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.043, suggesting its more volatile than the S&P 500 by 4.293%.
-
Which is a Better Dividend Stock PBE or BBC?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.05%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 0.98% to investors and pays a quarterly dividend of $0.24 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or BBC?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns PBE or BBH?
VanEck Biotech ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat VanEck Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- BBHVanEck Biotech ETF-- -- -- -
What do Analysts Say About PBE or BBH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than VanEck Biotech ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than VanEck Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 BBHVanEck Biotech ETF0 0 0 -
Is PBE or BBH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.819, which suggesting that the stock is 18.07% less volatile than S&P 500. In comparison VanEck Biotech ETF has a beta of 0.727, suggesting its less volatile than the S&P 500 by 27.303%.
-
Which is a Better Dividend Stock PBE or BBH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.05%. VanEck Biotech ETF offers a yield of 0.79% to investors and pays a quarterly dividend of $1.25 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. VanEck Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or BBH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than VanEck Biotech ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than VanEck Biotech ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while VanEck Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for VanEck Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- BBHVanEck Biotech ETF-- -- -- --
-
Which has Higher Returns PBE or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or PJP?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is PBE or PJP More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.819, which suggesting that the stock is 18.07% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.580, suggesting its less volatile than the S&P 500 by 42.037%.
-
Which is a Better Dividend Stock PBE or PJP?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.05%. Invesco Pharmaceuticals ETF offers a yield of 0.97% to investors and pays a quarterly dividend of $0.22 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or PJP?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns PBE or PTH?
Invesco Dorsey Wright Healthcare Momentum ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat Invesco Dorsey Wright Healthcare Momentum ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- PTHInvesco Dorsey Wright Healthcare Momentum ETF-- -- -- -
What do Analysts Say About PBE or PTH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Dorsey Wright Healthcare Momentum ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than Invesco Dorsey Wright Healthcare Momentum ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than Invesco Dorsey Wright Healthcare Momentum ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 PTHInvesco Dorsey Wright Healthcare Momentum ETF0 0 0 -
Is PBE or PTH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.819, which suggesting that the stock is 18.07% less volatile than S&P 500. In comparison Invesco Dorsey Wright Healthcare Momentum ETF has a beta of 0.830, suggesting its less volatile than the S&P 500 by 16.97%.
-
Which is a Better Dividend Stock PBE or PTH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.05%. Invesco Dorsey Wright Healthcare Momentum ETF offers a yield of 0.06% to investors and pays a quarterly dividend of $0.03 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. Invesco Dorsey Wright Healthcare Momentum ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or PTH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than Invesco Dorsey Wright Healthcare Momentum ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than Invesco Dorsey Wright Healthcare Momentum ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while Invesco Dorsey Wright Healthcare Momentum ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for Invesco Dorsey Wright Healthcare Momentum ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- PTHInvesco Dorsey Wright Healthcare Momentum ETF-- -- -- --
-
Which has Higher Returns PBE or XPH?
SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Invesco Biotechnology & Genome ETF's net margin of --. Invesco Biotechnology & Genome ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBEInvesco Biotechnology & Genome ETF-- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About PBE or XPH?
Invesco Biotechnology & Genome ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Invesco Biotechnology & Genome ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe Invesco Biotechnology & Genome ETF is more attractive than SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings PBEInvesco Biotechnology & Genome ETF0 0 0 XPHSPDR S&P Pharmaceuticals ETF0 0 0 -
Is PBE or XPH More Risky?
Invesco Biotechnology & Genome ETF has a beta of 0.819, which suggesting that the stock is 18.07% less volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.759, suggesting its less volatile than the S&P 500 by 24.059%.
-
Which is a Better Dividend Stock PBE or XPH?
Invesco Biotechnology & Genome ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0.05%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.56% to investors and pays a quarterly dividend of $0.15 per share. Invesco Biotechnology & Genome ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBE or XPH?
Invesco Biotechnology & Genome ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Invesco Biotechnology & Genome ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Invesco Biotechnology & Genome ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invesco Biotechnology & Genome ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBEInvesco Biotechnology & Genome ETF-- -- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
